Dexxon, SoftBank and Sumitomo Dainippon-backed medical company builder Roivant Sciences will get a public listing through the transaction.

Roivant Sciences, the US-based biopharmaceutical company backed by telecommunications and internet group SoftBank and pharmaceutical firms Sumitomo Dainippon Pharma and Dexxon, agreed a reverse merger yesterday at a combined $7.3bn valuation. The deal will take place with Montes Archimedes Acquisition Corp, a special purpose acquisition company sponsored by healthcare investment firm Patient Square Capital, which…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.